PMID- 33724696
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210719
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 10
IP  - 8
DP  - 2021 Apr
TI  - Interphase fluorescence in situ hybridization analysis of CD19-selected cells: 
      Utility in detecting disease in post-therapy samples of B-cell neoplasms.
PG  - 2680-2689
LID - 10.1002/cam4.3853 [doi]
AB  - CONTEXT: The detection of low-level persistent or relapsed B-cell neoplasms, 
      particularly post-therapy, can be challenging, often requiring multiple testing 
      modalities. OBJECTIVE: Here we investigate the utility of CD19-based selection of 
      neoplastic B-cells (CD19S) as an enrichment strategy to improve the detection 
      rate of cytogenetic abnormalities in post-therapy samples of B-cell neoplasms, 
      especially those with low-level disease. DESIGN: In a cohort largely comprised of 
      post-therapy B-ALL and CLL samples, we performed fluorescence in situ 
      hybridization (FISH) analysis on CD19-selected cells (CD19S FISH) in 128 
      specimens from 88 patients, and on non-selected cells (NS FISH) in a subset of 
      cases. The FISH findings were compared with the concurrent flow cytometry (FC) 
      results in all samples and molecular analysis in a subset. RESULTS: CD19S FISH 
      was able to detect cytogenetic aberrations in 86.0% of post-therapy samples with 
      evidence of disease as determined by routine or MRD FC, compared to 59.1% of 
      samples by NS FISH. CD19S FISH detected significantly higher percentages of 
      positive cells compared to NS FISH (p < 0.001). Importantly, CD19S FISH enabled 
      the detection of emergent subclones (clonal evolution) associated with poor 
      prognosis. CONCLUSIONS: CD19S FISH can be useful in daily diagnostic practice. 
      Compared to NS FISH, CD19S FISH is quantitatively and qualitatively superior for 
      the detection of cytogenetic aberrations in B-cell neoplasms, which are important 
      for risk stratification and optimal management of patients with B-cell neoplasms, 
      especially in the relapsed setting. Although CD19S FISH has a diagnostic 
      sensitivity inferior to that of MRD FC, the sensitivity of this modality is 
      comparable to routine FC for the evaluation of low-level disease in the 
      post-therapy setting. Moreover, CD19S samples are invaluable for additional 
      molecular and genetic analyses.
CI  - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Parrott, Andrew M
AU  - Parrott AM
AUID- ORCID: 0000-0002-7845-7479
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center and NewYork-Presbyterian Hospital, New York, NY, USA.
FAU - Murty, Vundavalli V
AU  - Murty VV
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center and NewYork-Presbyterian Hospital, New York, NY, USA.
FAU - Walsh, Caitlin
AU  - Walsh C
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center and NewYork-Presbyterian Hospital, New York, NY, USA.
FAU - Christiano, Alecia
AU  - Christiano A
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center and NewYork-Presbyterian Hospital, New York, NY, USA.
FAU - Bhagat, Govind
AU  - Bhagat G
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center and NewYork-Presbyterian Hospital, New York, NY, USA.
FAU - Alobeid, Bachir
AU  - Alobeid B
AD  - Department of Pathology and Cell Biology, Columbia University Irving Medical 
      Center and NewYork-Presbyterian Hospital, New York, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20210315
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD19/analysis/*immunology
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - *Chromosome Aberrations
MH  - Female
MH  - Flow Cytometry
MH  - Follow-Up Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - *Interphase
MH  - Lymphoma, B-Cell/drug therapy/genetics/immunology/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Young Adult
PMC - PMC8026942
OTO - NOTNLM
OT  - B-cell
OT  - CD19-selection
OT  - FISH
OT  - cytogenetics
OT  - flow cytometry
OT  - karyotype
OT  - leukemia
OT  - lymphoma
OT  - measurable residual disease
OT  - minimal disease
OT  - neoplasm
OT  - post-therapy
COIS- No conflicts of interest.
EDAT- 2021/03/17 06:00
MHDA- 2021/07/20 06:00
PMCR- 2021/03/15
CRDT- 2021/03/16 12:58
PHST- 2021/02/02 00:00 [revised]
PHST- 2020/12/14 00:00 [received]
PHST- 2021/02/19 00:00 [accepted]
PHST- 2021/03/17 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2021/03/16 12:58 [entrez]
PHST- 2021/03/15 00:00 [pmc-release]
AID - CAM43853 [pii]
AID - 10.1002/cam4.3853 [doi]
PST - ppublish
SO  - Cancer Med. 2021 Apr;10(8):2680-2689. doi: 10.1002/cam4.3853. Epub 2021 Mar 15.